CL2010000019A1 - Monoclonal antibody against human tnf and its fragments, nucleotide sequences that encode it, expression vector and cells containing them, compositions and kit comprising the antibody, use thereof and method for obtaining it. - Google Patents

Monoclonal antibody against human tnf and its fragments, nucleotide sequences that encode it, expression vector and cells containing them, compositions and kit comprising the antibody, use thereof and method for obtaining it.

Info

Publication number
CL2010000019A1
CL2010000019A1 CL2010000019A CL2010000019A CL2010000019A1 CL 2010000019 A1 CL2010000019 A1 CL 2010000019A1 CL 2010000019 A CL2010000019 A CL 2010000019A CL 2010000019 A CL2010000019 A CL 2010000019A CL 2010000019 A1 CL2010000019 A1 CL 2010000019A1
Authority
CL
Chile
Prior art keywords
fragments
compositions
obtaining
cells containing
encode
Prior art date
Application number
CL2010000019A
Other languages
Spanish (es)
Inventor
Gutierrez Juan Carlos Aguillon
Sampayo Maria Carmen Molina
Roa Rosa Elizabeth Pinilla
Original Assignee
Univ Chile
Bph S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Chile, Bph S A filed Critical Univ Chile
Priority to CL2010000019A priority Critical patent/CL2010000019A1/en
Publication of CL2010000019A1 publication Critical patent/CL2010000019A1/en
Priority to ARP110100057 priority patent/AR079860A1/en
Priority to UY33174A priority patent/UY33174A/en
Priority to PCT/EP2011/050282 priority patent/WO2011083175A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

LA INVENCIÓN SE RELACIONA CON LA RAMA DE LA BIOTECNOLOGIA Y EN PARTICULAR PROPORCIONA ANTICUERPOS MONOCLONALES OBTENIDOS CONTRA EL FACTOR DE NECROSIS TUMORAL (TNF) .LA INVENCIÓN TAMBIÉN INCLUYE LAS SECUENCIAS NUCLEOTIDICAS QUE CODIFICAN PARA LAS REGIONES INMUNOLÓGICAMENTE IMPORTANTES DE DICHOS ANTICUERPOS (CDRS) DE SUS CADENAS PESADAS Y LIVIANAS, LOS VECTORES DE EXPRESIÓN Y CÉLULAS HOSPEDERAS QUE CONTIENEN DICHAS SECUENCIAS NUCLEOTIDICAS. LOS FRAGMENTOS DE DICHOS ANTICUERPOS. LAS COMPOSICIONES Y KITS QUE CONTIENEN DICHOS ANTICUERPOS O FRAGMENTOS DE LOS MISMOS, ASI COMO CON EL MÉTODO DE OBTENCIÓN DE LOS ANTICUERPOS. LA INVENCION SE PUEDE UTILIZAR EN LA FABRICACION DE UN MEDICAMENTO PARA EL TRATAMIENTO DE ENFERMEDADES RELACIONADAS CON EL TNF.<br />  THE INVENTION IS RELATED TO THE BRANCH OF BIOTECHNOLOGY AND IN PARTICULAR PROVIDES MONOCLONAL ANTIBODIES OBTAINED AGAINST THE TUMOR NECROSIS FACTOR (TNF) .THE INVENTION ALSO INCLUDES THE NUCLEOTIDIC SEQUENCES THAT CODE DIFFERENT CERTIFICATES OF CODIFICATIONS HEAVY AND LIGHTWEIGHT, THE EXPRESSION VECTORS AND HOSPED CELLS CONTAINING SUCH NUCLEOTIDIC SEQUENCES. THE FRAGMENTS OF SUCH ANTIBODIES. THE COMPOSITIONS AND KITS CONTAINING SUCH ANTIBODIES OR FRAGMENTS OF THE SAME, AS WELL AS THE METHOD OF OBTAINING THE ANTIBODIES. THE INVENTION CAN BE USED IN THE MANUFACTURE OF A MEDICINAL PRODUCT FOR THE TREATMENT OF DISEASES RELATED TO TNF. <br />

CL2010000019A 2010-01-11 2010-01-11 Monoclonal antibody against human tnf and its fragments, nucleotide sequences that encode it, expression vector and cells containing them, compositions and kit comprising the antibody, use thereof and method for obtaining it. CL2010000019A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CL2010000019A CL2010000019A1 (en) 2010-01-11 2010-01-11 Monoclonal antibody against human tnf and its fragments, nucleotide sequences that encode it, expression vector and cells containing them, compositions and kit comprising the antibody, use thereof and method for obtaining it.
ARP110100057 AR079860A1 (en) 2010-01-11 2011-01-07 MONOCLONAL ANTIBODY ANTI-FACTOR OF TUMOR NECROSIS (TNF), SEQUENCES THAT DEFINE IT, COMPOSITIONS THAT INCLUDE IT AND ITS APPLICATIONS
UY33174A UY33174A (en) 2010-01-11 2011-01-10 MONOCLONAL ANTIBODY ANTI-FACTOR OF TUMOR NECROSIS (TNF), SEQUENCES THAT DEFINE IT, COMPOSITIONS THAT INCLUDE IT AND ITS APPLICATIONS
PCT/EP2011/050282 WO2011083175A1 (en) 2010-01-11 2011-01-11 Monoclonal antibody anti-tumor necrosis factor (tnf), which defines sequences, compositions comprising it and its applications

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CL2010000019A CL2010000019A1 (en) 2010-01-11 2010-01-11 Monoclonal antibody against human tnf and its fragments, nucleotide sequences that encode it, expression vector and cells containing them, compositions and kit comprising the antibody, use thereof and method for obtaining it.

Publications (1)

Publication Number Publication Date
CL2010000019A1 true CL2010000019A1 (en) 2010-06-11

Family

ID=43797518

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2010000019A CL2010000019A1 (en) 2010-01-11 2010-01-11 Monoclonal antibody against human tnf and its fragments, nucleotide sequences that encode it, expression vector and cells containing them, compositions and kit comprising the antibody, use thereof and method for obtaining it.

Country Status (4)

Country Link
AR (1) AR079860A1 (en)
CL (1) CL2010000019A1 (en)
UY (1) UY33174A (en)
WO (1) WO2011083175A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY183989A (en) * 2011-09-19 2021-03-17 Axon Neuroscience Se Protein-based therapy and diagnosis of tau-mediated pathology in alzheimer's disease
KR102622281B1 (en) 2015-03-31 2024-01-08 소리소 파마슈티컬스 인크. polypeptide
GB201522394D0 (en) 2015-12-18 2016-02-03 Ucb Biopharma Sprl Antibodies
CL2016001661A1 (en) 2016-06-29 2017-03-03 Univ Chile Hybrid promoter of ß-actin (from cricetulus griseus) and cytomegalovirus (cmv), with a region rich in dinucleotides, cytosine-guanine, vectors, cell lines, procedure to produce recombinant proteins.
EP3519438A1 (en) 2016-09-30 2019-08-07 VHsquared Limited Compositions
IL268568B2 (en) * 2017-02-10 2024-03-01 Mayo Found Medical Education & Res TRAILshort ANTIBODY AND METHODS OF USE
US20220242945A1 (en) 2019-06-21 2022-08-04 Sorriso Pharmaceuticals, Inc. Polypeptides
CN114466864A (en) 2019-06-21 2022-05-10 索瑞索制药公司 Polypeptides

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU668864B2 (en) * 1991-03-18 1996-05-23 Centocor Inc. Chimeric antibodies specific for human tumor necrosis factor
UA81743C2 (en) * 2000-08-07 2008-02-11 Центокор, Инк. HUMAN MONOCLONAL ANTIBODY WHICH SPECIFICALLY BINDS TUMOR NECROSIS FACTOR ALFA (TNFα), PHARMACEUTICAL MIXTURE CONTAINING THEREOF, AND METHOD FOR TREATING ARTHRITIS
CN101111521B (en) * 2004-12-29 2011-08-24 株式会社柳韩洋行 Humanized antibody specific for tumor necrosis factor-alpha
PL1919951T3 (en) * 2005-08-04 2015-07-31 Janssen Biotech Inc Anti-tnf-alpha antibodies and methods of use

Also Published As

Publication number Publication date
AR079860A1 (en) 2012-02-22
WO2011083175A1 (en) 2011-07-14
UY33174A (en) 2011-04-29

Similar Documents

Publication Publication Date Title
CL2010000019A1 (en) Monoclonal antibody against human tnf and its fragments, nucleotide sequences that encode it, expression vector and cells containing them, compositions and kit comprising the antibody, use thereof and method for obtaining it.
CL2016002689A1 (en) Humanized antibodies against the cell adhesion molecule related to carcinoembryonic antigen 1 (ceacam1)
PE20170772A1 (en) MONOCLONAL ANTI-CTLA4 ANTIBODY OR ITS ANTIGEN BINDING FRAGMENT, A PHARMACEUTICAL COMPOSITION AND USE
AR088941A1 (en) ANTI-FGFR2 ANTIBODIES AND THEIR USES
CO6280409A2 (en) ANTIMESOTHELINE ANTIBODIES AND USES OF THE SAME
MX2017001403A (en) Bispecific single chain antibody construct with enhanced tissue distribution.
PE20150643A1 (en) ANTI-JAGGED 1 / JAGGED 2 CROSS-REACTIVE ANTIBODIES ACTIVABLE ANTI-JAGGED ANTIBODIES AND METHODS OF USE OF THEM
EA201890383A8 (en) CONSTRUCTIONS OF SPECIFIC ANTIBODIES BINDING WITH MESOTELIN AND CD3 (CD3)
UY35286A (en) Antibody constructs for CDH19 and CD3
CL2015002526A1 (en) Anti-ox40 antibodies and methods of use thereof (divisional of 545-13).
CL2011000672A1 (en) Antibody that binds to human il-17; nucleic acid encoding it; expression vector; Cellphone line; Method of production; pharmaceutical composition that includes it and its use to treat rheumatoid arthritis among other diseases.
AR111288A1 (en) ANTI-PHF-TAU ANTIBODIES AND ITS USES
AR053608A1 (en) ANTI-GM-CSF ANTIBODIES AND USES OF THE SAME
AR069681A1 (en) OX40 HUMAN RECEIVER UNION MOLECULES
EA201492101A1 (en) ANTIBODIES AGAINST FCRN
CL2008002015A1 (en) Hepatocyte growth factor (hgf) anti-receptor antibody / c-met receptor; hybridoma that produces it; nucleic acid encoding it; vector and host cell that includes them; production procedure; composition that understands them; its use to treat cancer; and in vitro diagnostic method
AR063840A1 (en) MONOCLONAL HUMAN ANTIBODIES FOR BTLA AND METHODS OF USE
CL2011002039A1 (en) Humanized antibody that binds to human cd19; isolated nucleic acid encoding said antibody; vector and host cell; composition and immunoconjugate; method to inhibit the growth of tumor cells expressing cd19.
BR112012023010A2 (en) &#34;antibody or antigen binding fragment thereof which specifically binds to cd37, immunoconjugate comprising them, use of said antibody, fragment and immunoconjugate, composition comprising them, kit, isolated cell, as well as in vitro method for inhibiting growth&#34; of a cell expressing cd37 &#34;
EA202092735A1 (en) ANTAGONIZING CD73 ANTIBODY
NI201700012A (en) PROTEIN KINASE C INHIBITORS AND METHODS OF THEIR USE
ECSP099619A (en) ANTI-ROBO4 ANTIBODIES AND THEIR USES
AR073072A1 (en) HUMAN ANTIBODIES FOR THE BINDING OF THE HUMAN NF-KB RECEIVER ACTIVATOR (RANKL)
CL2011000730A1 (en) Selection procedure for anti-cxcr4 antibodies and selected antibodies; nucleic acid encoding the antibodies; vector; host cell; production procedure; hybridoma that produces the antibodies; composition; use of selected antibodies to prepare a medicine to treat cancer.
CL2009000567A1 (en) Monoclonal antibody that specifically binds human tyrp1; fragment of any of the antibodies indicated above; nucleic acid encoding antibody or fragment; expression vector; recombinant cell; use of the antibody or fragment to treat cancer.